The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1LAIPX     2-hydroxy-1,3-dimethyl- pyridin-4-one

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of deferiprone


High impact information on deferiprone


Chemical compound and disease context of deferiprone


Biological context of deferiprone


Anatomical context of deferiprone


Associations of deferiprone with other chemical compounds


Gene context of deferiprone

  • These studies have identified chelators such as 1,6-dimethyl-2-(N-4',N-propylsuccinamido)methyl-3-hydroxypyridin-4-one (CP358), which causes only a 10% inhibition of 5-LO after 24 h of incubation at 110 microm IBE (iron-binding equivalents) in comparison to simple dialkyl HPOs such as Deferiprone (CP20) which cause up to 70% inhibition [26].
  • Deferiprone (HK1), which showed the highest tumor specificity, had 10 times higher cytotoxicity than maltol (HK3) in both human promyelocytic leukemia HL-60 and human oral squamous cell carcinoma HSC-2 cell lines [27].
  • Hydroxyketone chelators, deferiprone (HK1), maltol (HK3) and their related compounds (HK2, 4-8), were characterized for their cytotoxic profiles against oral human normal and tumor cells [27].
  • Treatment of cultured HM with a lipophilic iron chelator (deferiprone) abrogates LPS-induced NF-kappaB activation [28].
  • In PBL, p24 reduction was mirrored by a decrease in proliferation after incubation with deferoxamine or deferiprone, suggesting that viral inhibition is closely linked to a decrease in cellular proliferation [29].

Analytical, diagnostic and therapeutic context of deferiprone


  1. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D., Fleming, K.A. N. Engl. J. Med. (1998) [Pubmed]
  2. Deferiprone in iron overload. Hoffbrand, A.V., Wonke, B. N. Engl. J. Med. (1995) [Pubmed]
  3. Arthropathy in thalassaemia patients receiving deferiprone. Berkovitch, M., Laxer, R.M., Inman, R., Koren, G., Pritzker, K.P., Fritzler, M.J., Olivieri, N.F. Lancet (1994) [Pubmed]
  4. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Wanless, I.R., Sweeney, G., Dhillon, A.P., Guido, M., Piga, A., Galanello, R., Gamberini, M.R., Schwartz, E., Cohen, A.R. Blood (2002) [Pubmed]
  5. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Anderson, L.J., Wonke, B., Prescott, E., Holden, S., Walker, J.M., Pennell, D.J. Lancet (2002) [Pubmed]
  6. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Fabio, G., Minonzio, F., Delbini, P., Bianchi, A., Cappellini, M.D. Blood (2007) [Pubmed]
  7. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Tanner, M.A., Smith, G.C., Westwood, M.A., Wonke, B., Galanello, R. Blood (2006) [Pubmed]
  8. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Hoffbrand, A.V., AL-Refaie, F., Davis, B., Siritanakatkul, N., Jackson, B.F., Cochrane, J., Prescott, E., Wonke, B. Blood (1998) [Pubmed]
  9. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Glickstein, H., El, R.B., Link, G., Breuer, W., Konijn, A.M., Hershko, C., Nick, H., Cabantchik, Z.I. Blood (2006) [Pubmed]
  10. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. Ibrahim, A.S., Edwards, J.E., Fu, Y., Spellberg, B. J. Antimicrob. Chemother. (2006) [Pubmed]
  11. Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. Ablin, J., Shalev, O., Okon, E., Karmeli, F., Rachmilewitz, D. Inflamm. Bowel Dis. (1999) [Pubmed]
  12. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. al-Refaie, F.N., Sheppard, L.N., Nortey, P., Wonke, B., Hoffbrand, A.V. Br. J. Haematol. (1995) [Pubmed]
  13. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes. Maclean, K.H., Cleveland, J.L., Porter, J.B. Blood (2001) [Pubmed]
  14. Effect of nitric oxide on iron-mediated oxidative stress in primary rat hepatocyte culture. Sergent, O., Griffon, B., Morel, I., Chevanne, M., Dubos, M.P., Cillard, P., Cillard, J. Hepatology (1997) [Pubmed]
  15. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats. Brissot, P., Bolder, U., Schteingart, C.D., Arnaud, J., Hofmann, A.F. Hepatology (1997) [Pubmed]
  16. Glutathione depletion increases nitric oxide-induced oxidative stress in primary rat hepatocyte cultures: involvement of low-molecular-weight iron. Sinbandhit-Tricot, S., Cillard, J., Chevanne, M., Morel, I., Cillard, P., Sergent, O. Free Radic. Biol. Med. (2003) [Pubmed]
  17. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Shalev, O., Repka, T., Goldfarb, A., Grinberg, L., Abrahamov, A., Olivieri, N.F., Rachmilewitz, E.A., Hebbel, R.P. Blood (1995) [Pubmed]
  18. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Barnabé, N., Zastre, J.A., Venkataram, S., Hasinoff, B.B. Free Radic. Biol. Med. (2002) [Pubmed]
  19. Antiproliferative effect of deferiprone on the Hep G2 cell line. Chenoufi, N., Drénou, B., Loréal, O., Pigeon, C., Brissot, P., Lescoat, G. Biochem. Pharmacol. (1998) [Pubmed]
  20. Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Arthur, A.S., Fergus, A.H., Lanzino, G., Mathys, J., Kassell, N.F., Lee, K.S. Neurosurgery (1997) [Pubmed]
  21. Kinetic studies on the removal of iron and aluminum from recombinant and site-directed mutant N-lobe half transferrins. Li, Y., Harris, W.R., Maxwell, A., MacGillivray, R.T., Brown, T. Biochemistry (1998) [Pubmed]
  22. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Kontoghiorghes, G.J. The Analyst. (1995) [Pubmed]
  23. Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone. Czachor, J.D., Cherian, M.G., Koropatnick, J. J. Inorg. Biochem. (2002) [Pubmed]
  24. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Emara, A.M., El Kelany, R.S., Moustafa, K.A. Human & experimental toxicology. (2006) [Pubmed]
  25. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Kontoghiorghes, G.J., Barr, J., Baillod, R.A. Arzneimittel-Forschung. (1994) [Pubmed]
  26. Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase. Kayyali, R., Porter, J.B., Liu, Z.D., Davies, N.A., Nugent, J.H., Cooper, C.E., Hider, R.C. J. Biol. Chem. (2001) [Pubmed]
  27. Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines. Yasumoto, E., Nakano, K., Nakayachi, T., Morshed, S.R., Hashimoto, K., Kikuchi, H., Nishikawa, H., Kawase, M., Sakagami, H. Anticancer Res. (2004) [Pubmed]
  28. Iron regulation of hepatic macrophage TNFalpha expression. Tsukamoto, H. Free Radic. Biol. Med. (2002) [Pubmed]
  29. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. Georgiou, N.A., van der Bruggen, T., Oudshoorn, M., Nottet, H.S., Marx, J.J., van Asbeck, B.S. J. Infect. Dis. (2000) [Pubmed]
  30. Role of deferiprone in chelation therapy for transfusional iron overload. Hoffbrand, A.V., Cohen, A., Hershko, C. Blood (2003) [Pubmed]
  31. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Kontoghiorghes, G.J., Neocleous, K., Kolnagou, A. Drug safety : an international journal of medical toxicology and drug experience. (2003) [Pubmed]
  32. Orally active iron chelators. Merson, L., Olivier, N. Blood Rev. (2002) [Pubmed]
  33. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Mourad, F.H., Hoffbrand, A.V., Sheikh-Taha, M., Koussa, S., Khoriaty, A.I., Taher, A. Br. J. Haematol. (2003) [Pubmed]
WikiGenes - Universities